Skip to main navigation Skip to search Skip to main content

A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients

  • I.E.L.M. Kuppens
  • , E.O. Witteveen
  • , R.C. Jewell
  • , S.A Radema
  • , E.M. Paul
  • , S.G. Mangum
  • , J.H. Beijnen
  • , E.E. Voest
  • , J.H.M. Schellens
  • extern

Research output: Contribution to journal › Article › Academic › peer-review

Original languageUndefined/Unknown
Pages (from-to)3276-3285
Number of pages10
JournalClinical Cancer Research
Volume13
Issue number11
Publication statusPublished - 2007

Bibliographical note

1078-0432

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this